Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma.

Glass JO, Ogg RJ, Hyun JW, Harreld JH, Schreiber JE, Palmer SL, Li Y, Gajjar AJ, Reddick WE.

Neuro Oncol. 2017 Oct 1;19(10):1408-1418. doi: 10.1093/neuonc/nox062.

2.

Pineoblastoma-The Experience at St. Jude Children's Research Hospital.

Parikh KA, Venable GT, Orr BA, Choudhri AF, Boop FA, Gajjar AJ, Klimo P Jr.

Neurosurgery. 2017 Jul 1;81(1):120-128. doi: 10.1093/neuros/nyx005.

PMID:
28327927
3.

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF.

Drug Metab Dispos. 2016 Jul;44(7):1116-22. doi: 10.1124/dmd.115.068676. Epub 2016 Apr 6.

4.

Medulloblastoma-translating discoveries from the bench to the bedside.

Gajjar AJ, Robinson GW.

Nat Rev Clin Oncol. 2014 Dec;11(12):714-22. doi: 10.1038/nrclinonc.2014.181. Epub 2014 Oct 28. Review.

PMID:
25348790
5.

Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience.

Van Poppel M, Klimo P Jr, Dewire M, Sanford RA, Boop F, Broniscer A, Wright K, Gajjar AJ.

J Neurosurg Pediatr. 2011 Sep;8(3):251-6. doi: 10.3171/2011.6.PEDS11158.

PMID:
21882915
6.

Challenging issues in pediatric oncology.

Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS.

Nat Rev Clin Oncol. 2011 Jun 28;8(9):540-9. doi: 10.1038/nrclinonc.2011.95. Review.

7.

Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF.

J Clin Oncol. 2009 Sep 20;27(27):4599-604. doi: 10.1200/JCO.2008.19.6642. Epub 2009 Aug 17.

8.

Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.

Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM.

J Clin Oncol. 2006 Feb 1;24(4):563-70.

PMID:
16446328
9.

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF.

J Clin Oncol. 2004 Mar 1;22(5):829-37.

PMID:
14990638
10.

A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.

Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF.

Math Biosci. 2003 Nov;186(1):29-41.

PMID:
14527745
11.

Urolithiasis in pediatric patients with acute lymphoblastic leukemia.

Howard SC, Kaplan SD, Razzouk BI, Rivera GK, Sandlund JT, Ribeiro RC, Rubnitz JE, Gajjar AJ, Ke W, Hancock ML, Skoch JP, Roy S, Hudson M, Pui CH.

Leukemia. 2003 Mar;17(3):541-6.

PMID:
12646942
12.

Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.

Howard SC, Gajjar AJ, Cheng C, Kritchevsky SB, Somes GW, Harrison PL, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, de Armendi AJ, Razzouk BI, Pui CH.

JAMA. 2002 Oct 23-30;288(16):2001-7.

PMID:
12387652
13.

Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells.

Yeoh EJ, Cunningham JM, Yee GC, Hunt D, Houston JA, Richardson SL, Stewart CF, Houghton PJ, Bowman LC, Gajjar AJ.

Bone Marrow Transplant. 2001 Sep;28(6):563-71.

14.

Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.

Woo MH, Hak LJ, Storm MC, Gajjar AJ, Sandlund JT, Harrison PL, Wang B, Pui CH, Relling MV.

J Clin Oncol. 1999 May;17(5):1568-73.

PMID:
10334545
15.

Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.

Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF.

Cancer Chemother Pharmacol. 1999;43(6):454-60.

PMID:
10321504
16.

A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.

Zamboni WC, Gajjar AJ, Mandrell TD, Einhaus SL, Danks MK, Rogers WP, Heideman RL, Houghton PJ, Stewart CF.

Clin Cancer Res. 1998 Oct;4(10):2537-44.

17.

Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF.

Clin Cancer Res. 1998 Mar;4(3):783-9.

18.

Supratentorial malignant gliomas in childhood: a single institution perspective.

Heideman RL, Kuttesch J Jr, Gajjar AJ, Walter AW, Jenkins JJ, Li Y, Sanford RA, Kun LE.

Cancer. 1997 Aug 1;80(3):497-504.

PMID:
9241084
19.

Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors.

Heideman RL, Kovnar EH, Kellie SJ, Douglass EC, Gajjar AJ, Walter AW, Langston JA, Jenkins JJ, Li Y, Greenwald C, et al.

J Clin Oncol. 1995 Sep;13(9):2247-54.

PMID:
7666082
20.

Relation of tumor-cell ploidy to survival in children with medulloblastoma.

Gajjar AJ, Heideman RL, Douglass EC, Kun LE, Kovnar EH, Sanford RA, Fairclough DL, Ayers D, Look AT.

J Clin Oncol. 1993 Nov;11(11):2211-7.

PMID:
8229136

Supplemental Content

Loading ...
Support Center